FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
CJC-1295 No DAC + Ipamorelin 5/5mg research peptide vial
Growth & Longevity

CJC-1295 No DAC + Ipamorelin

GH secretagogue blend

A synergistic GH-axis research blend of CJC-1295 No DAC and ipamorelin.

$98

In stock · ships in 1–2 business days

  • ✓ 99.82% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
blendGH research

Research Summary

This blend pairs the GHRH analog CJC-1295 No DAC with the selective secretagogue ipamorelin, a combination studied in preclinical research for complementary growth-hormone-release pathways. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

CJC-1295 No DAC + Ipamorelin: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is this blend?

This product combines two research peptides that act on different receptors in the growth hormone (GH) axis: CJC-1295 No DAC, an analog of growth hormone-releasing hormone (GHRH), and ipamorelin, a selective agonist of the ghrelin receptor. Each vial holds 5mg of each peptide as a single lyophilized powder.

It is offered as a convenience format for laboratories that already study both compounds. Its components are sold individually as CJC-1295 No DAC and ipamorelin, and researchers who need independent control of each compound, or single-agent arms, should use those instead.

The published research on this exact two-compound combination is limited. The sections below summarize what is known about each component and are explicit about what has not been studied.

CJC-1295 No DAC + Ipamorelin molecular identity
CompositionCJC-1295 No DAC 5mg + ipamorelin 5mg per vial (lyophilized)
CJC-1295 No DAC: descriptionTetrasubstituted hGRF(1-29) amide, 29 residues, without the maleimidopropionyl lysine of the DAC form (no PubChem compound record)
CJC-1295 No DAC: targetGHRH receptor
Ipamorelin: sequenceAib-His-D-2-Nal-D-Phe-Lys-NH2
Ipamorelin: formula and weightC38H49N9O5, 711.9 g/mol
Ipamorelin: CAS and PubChem CID170851-70-4; CID 9831659
Ipamorelin: targetGhrelin receptor (GHS-R1a)

The two components

CJC-1295 No DAC

CJC-1295 with DAC was characterized in 2005 as a tetrasubstituted form of hGRF(1-29) with an added C-terminal lysine carrying a maleimidopropionamide group that binds serum albumin [1]. The "No DAC" form lacks that albumin-binding lysine. A Norwegian doping-control laboratory reported in 2010 that a preparation sold under the CJC-1295 name contained a 29-amino-acid peptide with a C-terminal amide, illustrating that the non-DAC form circulates under the same name [2]. Anti-doping chemists handle "CJC-1295" and "CJC-1295 with drug affinity complex" as distinct analytes [3]. Without albumin binding, the non-DAC form would not be expected to share the extended persistence reported for the DAC form; we found no peer-reviewed pharmacokinetic study of the non-DAC form itself.

Ipamorelin

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described in 1998 as the first GH secretagogue with a selectivity for GH release similar to that of GHRH. In swine it did not raise ACTH or cortisol beyond the levels seen after GHRH, whereas GHRP-2 and GHRP-6 did [4] [5]. See the ipamorelin research page for its full literature.

Two receptors, two pathways

The scientific rationale for studying these compounds side by side is that GH release from the pituitary is regulated through more than one receptor system.

  • GHRH receptor. GHRH is synthesized in the hypothalamus and binds receptors on pituitary somatotroph cells to promote GH synthesis and release [6]. CJC-1295 analogs are built on the hGRF(1-29) fragment of GHRH [1].
  • Ghrelin receptor. A distinct G protein-coupled receptor in the pituitary and hypothalamus, cloned in 1996, is the target of synthetic GH secretagogues [7]. Its endogenous ligand, ghrelin, was identified in 1999, and its discoverers noted that GH release may therefore be regulated not only by hypothalamic GHRH but also by ghrelin [8].

The two systems are linked rather than independent. In rats, the GH response to the ghrelin-receptor agonist GHRP-2 was absent after hypophysectomy and reduced after median eminence lesions, indicating that endogenous GHRH input was needed for the full response [9]. In GHRH knockout mice, long-term GHRP-2 exposure failed to stimulate GH secretion or somatotroph proliferation [10]. These findings come from GHRP-2, not ipamorelin, and they describe how the pathways depend on each other; they do not show what a fixed combination of these two specific compounds does.

What has and has not been studied

Being clear about the gaps matters for this product:

  • No combination studies identified. We found no peer-reviewed study in PubMed that tested CJC-1295 No DAC and ipamorelin together. Claims elsewhere that the two are "synergistic" are not supported by published data on this combination, and Rejuvatide makes no such claim.
  • Component data are uneven. Ipamorelin has published animal pharmacology, a human pharmacokinetic study, and a phase 2 trial in postoperative ileus that found no significant difference from placebo on its efficacy measures [11] [12]. The published human pharmacology for CJC-1295 concerns the DAC form, not the non-DAC component in this vial [13].
  • Unregulated use. A 2026 narrative review of GH-axis peptides used outside medical supervision listed both CJC-1295 without DAC and ipamorelin, highlighted uncertainty about product composition, and described a gap between the clinical evidence and unsupervised use [14].

Any research use of the blend should be designed with that limited evidence base in mind, ideally alongside single-component controls.

Regulatory status

  • Not FDA approved. A search of Drugs@FDA on October 12, 2026 returned no approved drug product containing CJC-1295 or ipamorelin [15].
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) places ipamorelin acetate in category 2 under the 503B interim policy (added September 29, 2023) and lists CJC-1295 among substances whose nominations were withdrawn, with FDA noting immunogenicity risk and reported serious adverse events for both [16].
  • Sport. The World Anti-Doping Agency 2026 Prohibited List names CJC-1295 (among GHRH analogues) and ipamorelin (among growth hormone secretagogues) under S2.2.4, growth hormone releasing factors, within class S2, which is prohibited at all times [17].

Status checked October 12, 2026. Rejuvatide supplies this blend strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

This blend is tested as a finished product by an independent laboratory, with identity confirmed for both components by LC-MS and purity by HPLC, and it is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Single-component material for control arms: CJC-1295 No DAC and ipamorelin. For the long-acting albumin-binding analog, see CJC-1295 with DAC. Browse all growth-axis research peptides.

Storage of lyophilized material

This blend ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of CJC-1295 No DAC + Ipamorelin.

99.82%HPLC purity
Lot 60730-10Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

CJC-1295 No DAC + Ipamorelin FAQ

What is in the CJC-1295 No DAC + Ipamorelin blend?

Each vial contains 5mg of CJC-1295 No DAC, a GHRH analog, and 5mg of ipamorelin, a selective ghrelin-receptor agonist, as one lyophilized powder.

Is the combination synergistic?

We found no peer-reviewed study testing these two peptides together, so Rejuvatide makes no synergy claim. The components act on different receptors, the GHRH receptor and the ghrelin receptor, which is why researchers study them side by side.

Does this blend contain CJC-1295 with DAC?

No. It contains the non-DAC form, which lacks the albumin-binding lysine. CJC-1295 with DAC is sold separately.

Should a study use the blend or the single peptides?

If your study needs independent control of each compound or single-agent arms, use the individual CJC-1295 No DAC and ipamorelin products. The blend is a convenience format for work that already uses both.

How is the blend tested?

The finished blend is tested by an independent laboratory for identity by LC-MS, purity by HPLC, and endotoxin. Certificates are on the product page and in the COA library.

Are these peptides banned in sport?

Yes. WADA lists CJC-1295 and ipamorelin under S2.2.4, growth hormone releasing factors, prohibited at all times.

Is this blend for human use?

No. Rejuvatide sells it for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. Jetté L, Léger R, Thibaudeau K, et al. Endocrinology. 2005;146(7):3052-8. PubMed 15817669
  2. Henninge J, Pepaj M, Hullstein I, et al. Drug Test Anal. 2010;2(11-12):647-50. PubMed 21204297
  3. Memdouh S, Gavrilović I, Ng K, et al. Drug Test Anal. 2021;13(11-12):1871-1887. PubMed 34665524
  4. Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822
  5. PubChem. Ipamorelin, Compound CID 9831659. National Library of Medicine. Source
  6. Sackmann-Sala L, Ding J, Frohman LA, et al. Growth Horm IGF Res. 2009;19(6):471-7. PubMed 19386527
  7. Howard AD, Feighner SD, Cully DF, et al. Science. 1996;273(5277):974-7. PubMed 8688086
  8. Kojima M, Hosoda H, Date Y, et al. Nature. 1999;402(6762):656-60. PubMed 10604470
  9. Doi N, Hirotani C, Ukai K, et al. Arzneimittelforschung. 2004;54(12):857-67. PubMed 15646370
  10. Alba M, Fintini D, Bowers CY, et al. Am J Physiol Endocrinol Metab. 2005;289(5):E762-7. PubMed 15985453
  11. Gobburu JV, Agersø H, Jusko WJ, et al. Pharm Res. 1999;16(9):1412-6. PubMed 10496658
  12. Beck DE, Sweeney WB, McCarter MD. Int J Colorectal Dis. 2014;29(12):1527-34. PubMed 25331030
  13. Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683
  14. Dominikowski A, Rękoś Z, Olejarz M, et al. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  15. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs (searched October 12, 2026). Source
  16. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  17. World Anti-Doping Agency. The 2026 Prohibited List, S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. Source